PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17660247-0 2007 p53 regulates cyclophosphamide teratogenesis by controlling caspases 3, 8, 9 activation and NF-kappaB DNA binding. Cyclophosphamide 14-30 transformation related protein 53, pseudogene Mus musculus 0-3 9671594-2 1998 The purpose of this study was to investigate the role of the tumor suppressor/cell cycle checkpoint gene, p53, and of cell cycle arrest in the response of the limbs to cyclophosphamide. Cyclophosphamide 168-184 transformation related protein 53, pseudogene Mus musculus 106-109 20124494-0 2010 Initial insights regarding the role of p53 in maintaining sperm DNA integrity following treatment of mice with ethylnitrosourea or cyclophosphamide. Cyclophosphamide 131-147 transformation related protein 53, pseudogene Mus musculus 39-42 18953436-6 2008 Cyclophosphamide (CPM) induced a complete remission in p53 wild type TH-MYCN tumors, mirroring the sensitivity of childhood neuroblastoma to this agent. Cyclophosphamide 0-16 transformation related protein 53, pseudogene Mus musculus 55-58 18953436-6 2008 Cyclophosphamide (CPM) induced a complete remission in p53 wild type TH-MYCN tumors, mirroring the sensitivity of childhood neuroblastoma to this agent. Cyclophosphamide 18-21 transformation related protein 53, pseudogene Mus musculus 55-58 10495452-0 1999 Cellular events and the pattern of p53 protein expression following cyclophosphamide-initiated cell death in various organs of developing embryo. Cyclophosphamide 68-84 transformation related protein 53, pseudogene Mus musculus 35-38 10495452-1 1999 This study was aimed at characterizing the temporal patterns of cell responses and p53 protein expression in the limbs, head, and liver of embryos responding to cyclophosphamide (CP)-induced teratogenic insult. Cyclophosphamide 161-177 transformation related protein 53, pseudogene Mus musculus 83-86 9434797-4 1998 In contrast, the content of c-myb and p53 mRNA is greater (P < 0.05) in submandibular tissues of female relative to those of male mice; and (3) testosterone or cyclophosphamide treatment led to a significant (P < 0.05) decline in the mRNA levels of c-myb, bcl-2, and/or AR, but an increase (P < 0.05) in the mRNA amount of Bax, in lacrimal, but not in salivary, glands of female mice. Cyclophosphamide 163-179 transformation related protein 53, pseudogene Mus musculus 38-41 31562295-6 2019 Cyclophosphamide exposure induced the activation of both DNAPK-gammaH2AX-checkpoint kinase 2 (CHK2)-p53/TAp63alpha isoform and protein kinase B (AKT)-forkhead box O3 (FOXO3a) signaling axes in the nucleus of oocytes. Cyclophosphamide 0-16 transformation related protein 53, pseudogene Mus musculus 100-103 28300840-0 2017 Ganetespib synergizes with cyclophosphamide to improve survival of mice with autochthonous tumors in a mutant p53-dependent manner. Cyclophosphamide 27-43 transformation related protein 53, pseudogene Mus musculus 110-113 27729272-0 2017 Cyclophosphamide promotes the proliferation inhibition of mouse ovarian granulosa cells and premature ovarian failure by activating the lncRNA-Meg3-p53-p66Shc pathway. Cyclophosphamide 0-16 transformation related protein 53, pseudogene Mus musculus 148-151 27729272-3 2017 The expressions of p53, p66Shc and p16 were significantly higher in OGCs of the cyclophosphamide treatment group. Cyclophosphamide 80-96 transformation related protein 53, pseudogene Mus musculus 19-22 27729272-6 2017 And, the expression of p53, p66Shc, p16 and cleaved caspase-3 in the OGCs of the cyclophosphamide treatment group significant increases. Cyclophosphamide 81-97 transformation related protein 53, pseudogene Mus musculus 23-26 27729272-8 2017 ChIP results confirmed the significant increase in the obtained p66Shc promoter DNA fragment, which was enriched on p53 protein, in the OGCs treated with cyclophosphamide. Cyclophosphamide 154-170 transformation related protein 53, pseudogene Mus musculus 116-119 27729272-9 2017 When cyclophosphamide treatment was conducted after siRNA-Meg3 was used, the expression of endogenous lncRNA-Meg3, p53, p66Shc, p16 and cleaved caspase-3 was significantly lower than that in the siRNA-Mock control group. Cyclophosphamide 5-21 transformation related protein 53, pseudogene Mus musculus 115-118 27729272-10 2017 In summary, cyclophosphamide promotes the proliferation inhibition of mouse OGCs and premature ovarian failure by activating the lncRNA-Meg3-p53-p66Shc pathway. Cyclophosphamide 12-28 transformation related protein 53, pseudogene Mus musculus 141-144 27856111-10 2016 All the above results together proposed that, DMSE sensitized tumor cells to cyclophosphamide therapy through ROS-induced p53 activation and mitochondria-mediated caspase dependent apoptosis. Cyclophosphamide 77-93 transformation related protein 53, pseudogene Mus musculus 122-125 12015983-3 2002 Hence, tumors with p53 or INK4a/ARF mutations-but not those lacking ARF alone-respond poorly to cyclophosphamide therapy in vivo. Cyclophosphamide 96-112 transformation related protein 53, pseudogene Mus musculus 19-22 15667832-8 2005 Additional analyses indicate that the tumor suppressor p53 and p53-regulated proapoptotic Bax were upregulated in vivo and in vitro following CPA treatment in combination with DOX, suggesting that upregulation of p53 may contribute to the enhancement of antitumor effect of CPA by DOX. Cyclophosphamide 142-145 transformation related protein 53, pseudogene Mus musculus 55-58 15667832-8 2005 Additional analyses indicate that the tumor suppressor p53 and p53-regulated proapoptotic Bax were upregulated in vivo and in vitro following CPA treatment in combination with DOX, suggesting that upregulation of p53 may contribute to the enhancement of antitumor effect of CPA by DOX. Cyclophosphamide 142-145 transformation related protein 53, pseudogene Mus musculus 63-66 15667832-8 2005 Additional analyses indicate that the tumor suppressor p53 and p53-regulated proapoptotic Bax were upregulated in vivo and in vitro following CPA treatment in combination with DOX, suggesting that upregulation of p53 may contribute to the enhancement of antitumor effect of CPA by DOX. Cyclophosphamide 142-145 transformation related protein 53, pseudogene Mus musculus 63-66 15667832-8 2005 Additional analyses indicate that the tumor suppressor p53 and p53-regulated proapoptotic Bax were upregulated in vivo and in vitro following CPA treatment in combination with DOX, suggesting that upregulation of p53 may contribute to the enhancement of antitumor effect of CPA by DOX. Cyclophosphamide 274-277 transformation related protein 53, pseudogene Mus musculus 55-58 15667832-8 2005 Additional analyses indicate that the tumor suppressor p53 and p53-regulated proapoptotic Bax were upregulated in vivo and in vitro following CPA treatment in combination with DOX, suggesting that upregulation of p53 may contribute to the enhancement of antitumor effect of CPA by DOX. Cyclophosphamide 274-277 transformation related protein 53, pseudogene Mus musculus 63-66 15667832-8 2005 Additional analyses indicate that the tumor suppressor p53 and p53-regulated proapoptotic Bax were upregulated in vivo and in vitro following CPA treatment in combination with DOX, suggesting that upregulation of p53 may contribute to the enhancement of antitumor effect of CPA by DOX. Cyclophosphamide 274-277 transformation related protein 53, pseudogene Mus musculus 63-66 15342414-2 2004 Here, we show that Fas as a p53 target plays important role in the HF response to cyclophosphamide. Cyclophosphamide 82-98 transformation related protein 53, pseudogene Mus musculus 28-31 11016618-2 2000 In a mouse model for chemotherapy-induced hair loss, we demonstrate that p53 is essential for this process: in contrast to wild-type mice, p53-deficient mice show neither hair loss nor apoptosis in the HF keratinocytes that maintained active proliferation after cyclophosphamide treatment. Cyclophosphamide 262-278 transformation related protein 53, pseudogene Mus musculus 73-76 10861484-0 2000 Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTL. Cyclophosphamide 0-16 transformation related protein 53, pseudogene Mus musculus 57-60 10861484-7 2000 We show here that CY acts synergistically with adoptively transferred wtp53-specific CTL in controlling the growth of an aggressive mutant p53-induced and overexpressing tumor. Cyclophosphamide 18-20 transformation related protein 53, pseudogene Mus musculus 72-75 10766175-6 2000 This antiangiogenic effect was more pronounced in p53-null mice in which the apoptosis of p53-null endothelial cells induced by cyclophosphamide was so vigorous that drug-resistant tumors comprising 4.5% of body weight were eradicated. Cyclophosphamide 128-144 transformation related protein 53, pseudogene Mus musculus 50-53 10766175-6 2000 This antiangiogenic effect was more pronounced in p53-null mice in which the apoptosis of p53-null endothelial cells induced by cyclophosphamide was so vigorous that drug-resistant tumors comprising 4.5% of body weight were eradicated. Cyclophosphamide 128-144 transformation related protein 53, pseudogene Mus musculus 90-93